Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Krystal Biotech's share price for the quarter that ended in Mar. 2026 was €215.2. Krystal Biotech's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 29.4 Mil. Therefore, Krystal Biotech's market cap for the quarter that ended in Mar. 2026 was €6,334.8 Mil.
Krystal Biotech's quarterly market cap
increased
from Sep. 2025 (€4,308.5 Mil) to Dec. 2025 (€6,252.9 Mil) and
increased
from Dec. 2025 (€6,252.9 Mil) to Mar. 2026 (€6,334.8 Mil).
Krystal Biotech's annual market cap
increased
from Dec. 2023 (€3,247.3 Mil) to Dec. 2024 (€4,358.0 Mil) and
increased
from Dec. 2024 (€4,358.0 Mil) to Dec. 2025 (€6,252.9 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Krystal Biotech's Enterprise Value for Today is €8,628.4 Mil.
Krystal Biotech (FRA:4KB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Krystal Biotech Market Cap Related Terms
Krystal Biotech Market Cap Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs NUVL, PRAX, TECH: Market Cap Comparison
For the Biotechnology subindustry, Krystal Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Krystal Biotech's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (FRA:4KB) has a Market Cap of €9,345.6 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Krystal Biotech and its competitors. According to the industry distribution chart, Krystal Biotech ranks #35 out of 1431 companies in the Biotechnology industry, placing it in the top 2.4%.
Is Krystal Biotech's Market Cap too high?
Krystal Biotech's current Market Cap is €9,345.6 Mil. Based on the distribution chart, Krystal Biotech ranks #35 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Market Cap compare to NUVL and PRAX?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #35 out of 1431 companies for Market Cap. This places Krystal Biotech in the top 2% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Krystal Biotech and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current Market Cap is €9,345.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €263.13, compared to a current price of €313.40 — trading 19.1% above its estimated fair value. The current Market Cap is €9,345.6 Mil. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Market Cap is €9,345.6 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €313.40 is trading 19.1% above its estimated GF Value™ of €263.13.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
Market Cap: €9,345.6 Mil
GF Value™: €263.13 vs. price of €313.40 (19.1% above fair value)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score
Get the complete analysis for FRA:4KB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
